Dupilumab Leads to Consistent Efficacy in Children (6-11 Years) with Type 2 Asthma Regardless of Baseline Demographics and Disease Characteristics

In VOYAGE (NCT02948959), dupilumab safely and significantly reduced asthma exacerbations and improved lung function in children aged 6–11 years with uncontrolled, moderate-to-severe type 2 asthma. Patient (age, gender, obesity) and disease (age at onset, exacerbations) characteristics are linked to asthma severity and may impact treatment outcomes. This post hoc analysis of VOYAGE assessed dupilumab efficacy in pre-specified subgroups of pediatric study patients.